Intrauterine Bone Marrow Transplantation in Osteogenesis Imperfecta Mice Yields Donor Osteoclasts and Osteomacs but Not Osteoblasts  by Millard, Susan M. et al.
Stem Cell Reports
ReportIntrauterine Bone Marrow Transplantation in Osteogenesis Imperfecta Mice
Yields Donor Osteoclasts and Osteomacs but Not Osteoblasts
Susan M. Millard,1,2,* Allison R. Pettit,1,2 Rebecca Ellis,1 Jerry K.Y. Chan,1,3,4 Liza J. Raggatt,1,2
Kiarash Khosrotehrani,1,5 and Nicholas M. Fisk1,6
1UQ Centre for Clinical Research, The University of Queensland, Herston, QLD 4029, Australia
2Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia
3Department of Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore 229899, Singapore
4Experimental Fetal Medicine Group, Department of Obstetrics and Gynaecology, National University of Singapore, Singapore 119228, Singapore
5UQ Diamantina Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia
6Royal Brisbane and Women’s Hospital, Centre for Advanced Prenatal Care, Herston, QLD 4029, Australia
*Correspondence: susan.millard@mater.uq.edu.au
http://dx.doi.org/10.1016/j.stemcr.2015.09.017
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).INTRODUCTION
Osteogenesis imperfecta (OI) represents a spectrum of
genetic disorders characterized by skeletal fragility and
low-impact fractures. Severity ranges from modest fracture
risk to extreme risk with intrauterine fractures and skeletal
malformations. Heterogeneity results from variability in
the range of causative mutations, with the vast majority
directly affecting the principle protein component of
bone, collagen type I, resulting in bone matrix of insuffi-
cient quantity and/or quality (Cundy, 2012). Bisphospho-
nates, anti-resorptive drugs that reduce bone turnover,
are commonly prescribed in severe OI; while they increase
bone mass, their efficacy in reducing fractures is less clear
(Dwan et al., 2014; Palomo et al., 2015). Furthermore, their
mode of action does not address the underlying cause of OI
and is associated with undesirable skeletal side effects in
children (Rauch et al., 2007).
Cell therapy has considerable potential in treating OI, as
replacing abnormal osteoblasts, the bone-forming cells
with defective bone matrix production, with normal func-
tioning osteoblasts should improve both bone quality and
quantity and mimic the naturally occurring mosaic muta-
tion carriers who demonstrate normal skeletal health
(Cabral and Marini, 2004). Thus, replacement of just 25%
of osteoblasts may deliver significant benefit to OI patients.
Small clinical trials and isolated case studies of cell therapy
for severe OI have already been undertaken, with consider-
able variation in transplantation protocols and donor cell
source. Growth velocity transiently improved in children
with OI following both bone marrow transplantation and
subsequent mesenchymal stromal/stem cell (MSC) trans-
plantation (Horwitz et al., 1999, 2001, 2002). Clinical expe-
rience following in utero transplantationof fetalMSC is also
consistent with modest transient benefit (Go¨therstro¨m
et al., 2014; Le Blanc et al., 2005). Given the low-level donor
chimerism reported, this cannot be conclusively attributed
to donor osteopoiesis. These few case studies are also subject682 Stem Cell Reports j Vol. 5 j 682–689 j November 10, 2015 j ª2015 Theto confounding factors ofbisphosphonate co-treatment and
inherent phenotypic heterogeneity ofOI.While promising,
thepotential of cell therapyhasyet tobe substantiatedand is
nowmore comprehensively addressed inpreclinical studies.
Preclinical models allow assessment of cell therapy in
larger sample sizes with more consistent disease presenta-
tion in the absence of confounding co-therapies. The key
target for cell replacement is the osteoblast that produces
the collagen type I bone matrix. As such, mesenchymal
stromal/stemcells (MSCs) are anobvious cell therapy candi-
date, as they are believed to be the source of long-term
osteoblast repopulation in vivo. However, a recent study
on adolescent osteogenesis imperfecta (oim/oim) mice
concluded non-adherent BM cells were superior to MSC at
contributing to osteopoiesis (Otsuru et al., 2012). Further-
more, intra-uterine transplantation of murine whole BM
in the Brtl IVmousemodel of OI reduced perinatal lethality
and was associated with improved bone biomechanics
(Panaroni et al., 2009). However, themethods to quantitate
chimerism were independent of rigorous confirmation of
donor cells being osteoblasts. This is of particular concern
following BM transplantation, where donor cells may
contribute to hematopoietic-derived bone cells, including
osteoclasts and osteal macrophages (Chang et al., 2008).
Hence, the capacity of donor cells to contribute to osteopoi-
esis following bone marrow transplantation remains
unclear. To address this, we profiled the identity of bone-
associated donor cells following intra-uterine bonemarrow
transplantation in the oim/oimmouse.RESULTS
Generation of oim/oimMice with Chimeric Bone
Marrow
Fetuses homozygous for a null mutation (oim) in the
collagen type I alpha 2 gene (COL1A2) underwent intra-
uterine bone marrow transplantation (BM-IUT) at e14.5,Authors
Figure 1. Generation of Osteogenesis
Imperfecta Mice with Chimeric Bone
Marrow
(A) Intrauterine transplantation of bone
marrow from adult CAG-EGFP mice was per-
formed on e14.5 oim/oim embryos, result-
ing in mice with low-level bone marrow
chimerism.
(B) Longitudinal humeral cryosection of
humerus displays strong correlation be-
tween endogenous GFP fluorescence and
GFP immunostaining. Scale bar, 200 mm.
GP, growth plate; Tb, trabecular bone.
Arrowheads indicate GFP+ cells in the bone
marrow. Arrows indicate GFP+ cells on the
bone surface.
(C) Quantitation of chimerism in six
individual 6-week-old mice by three
methods—enumeration of cells with either
endogenous GFP fluorescence or immuno-
staining for GFP (GFP IF) and quantitation
of donor DNA in femoral bone marrow (GFP
qPCR). Cell counts are means ±SD from at
least three cryosections.
(D) Distribution of GFP+ cells within
different regions of interest, as indicated.
Data shown for an individual mouse (E436)
are typical.receiving BM from GFP-expressing donors with wild-type
COL1A2 alleles (Figure 1A). BM-IUTwas performed in eight
pregnant mice and control injections in three pregnant
mice, resulting in 63 BM-IUT and 25 control oim/oim
fetuses. Of these, 22 (35%) BM-IUT and 13 (52%) control
neonates survived to P2, consistent with known fetal loss
rates following murine IUT (Chan et al., 2007; Panaroni
et al., 2009). Further losses occurred post-birth, consistent
with our experience with breeding homozygous oim/oim
without experimental intervention, such that 12 BM-IUT
(19% of transplanted fetuses) and four controls (16%) sur-
vived postnatally to the experimental endpoint of 6 weeks.
Chimerism was first assessed by qPCR to detect GFP
sequence in genomic DNA isolated from femoral BM.
GFP sequence was amplified in eight of 12 BM-IUT mice
(66%) but was not detectable in any controls. Of eight
chimeric mice, chimerism was quantifiable in four (range:
0.08%–1%; Figure 1C) but was at the assay detection limitStem Cell R(0.003%) in the other four animals. The identity of
chimeric animals was confirmed by immunofluorescent
staining for GFP in humeral sections. Antibody-mediated
staining co-localized with endogenous GFP fluorescence
(Figure 1B) and increased sensitivity of donor cell detection
by at least 30%. Enumeration of GFP+ cells in humeri,
identified by endogenous fluorescence (range: 116–2,146
GFP+ cells/section), correlated with chimerism rates in
femoral BM established by qPCR on gDNA (Figure 1C;
Spearman r 0.93, p < 0.02). Donor cell distribution was
assessed by dividing the humerus into five regions of inter-
est: epiphyses (humeral head), growth plate (cartilage),
trabecular bone surfaces (both primary and secondary
spongiosa), diaphyseal cortical surfaces, and BM of medul-
lar cavity. Donor cells were in all compartments except the
cartilaginous growth plate (Figure 1D). Cells associated
with bone surfaces (trabecular and cortical compartments,
and a portion of the epiphyseal compartment) typicallyeports j Vol. 5 j 682–689 j November 10, 2015 j ª2015 The Authors 683
Figure 2. The Majority of Bone Surface-
Associated Donor Cells Are Osteoclasts
(A) Representation of a longitudinal sec-
tion of the humerus showing three regions
of interest: (1) growth plate and primary
spongiosa, (2) epiphyseal, and (3) endo-
cortical.
(B and C) Images of region of interest 1
from humeral sections co-stained for donor
cells (GFP), osteoclasts (TRAP), and either
the osteoblast marker, osterix (B), or the
osteoclast-expressed galectin-3 (C). Insets
displayed at higher magnification show
mineralized cartilage and primary spon-
giosa (upper panel) and maturing trabec-
ular bone (lower panel). GP, growth plate.
Arrowheads indicate cells with broad TRAP+
staining. Arrows indicate cells with no
TRAP+ staining or punctate TRAP+ staining
consistent with osteoblastic endocytosis of
TRAP from the bone surface.
(D and E) Co-staining for donor cells (GFP)
and either osterix (D) or galectin-3
(E) within the epiphyses. Tb, trabecular
bone; AC, articular cartilage. GFP+ cells on
the bone surface within the epiphyses were
enumerated and the percentage of those
also positive for either osterix (D) or
galectin-3 (E) calculated. The average cell
counts from two sections are displayed.
Scale bars, 50 mm. See also Figure S1.accounted for more than 20% of GFP+ve donor cells
enumerated within each humerus.
Bone-Associated Donor Cells Are Osteoclasts and
Osteomacs, Not Osteoblasts
The identity of chimeric cells associated with the bone
surface was examined by staining for osterix (early osteo-
blast lineage commitment marker), galectin-3 (abundantly
expressed by osteoclasts and chondrocytes), and activity of
Tartrate-Resistant Acid Phosphatase (TRAP; a classical684 Stem Cell Reports j Vol. 5 j 682–689 j November 10, 2015 j ª2015 Themarker for osteoclasts). The highest frequency of bone-
associated donor cells was within trabecular bone of
primary spongiosa (Figures 2B and 2C) and the epiphyses
(Figures 2D and 2E). There was complete absence of
co-expression of osterix and GFP, in contrast to almost
complete overlap observed between GFP and galectin-3
staining on bone surfaces. Bone adjacent GFP+/galectin-3+
cells were also TRAP+, confirming their osteoclast identity.
Within non-bony regions (e.g., marrow, articular cartilage),
there was no overlap between GFP and galectin-3 staining,Authors
Figure 3. Some Endo-cortical-Associated Donor Cells Are
F4/80+ Osteal Macrophages
(A–C) Endo-cortical surface co-stained for donor cells (GFP)
and either osterix (A), galectin-3 (B), or the macrophage marker
F4/80 (C). bm, bone marrow; Ct, cortical bone. Scale bars, 50 mm.
Arrowheads indicate the location of GFP+ bone-associated donor
cells that are osterix negative, galectin-3 negative, and F4/80+.nor did GFP+ cells display TRAP+ staining (Figure 2E; data
not shown).
Histomorphometric analysis of the epiphysis revealed
complete absence of co-staining of GFP and the early oste-
oblast marker, osterix, within the context of abundant
single staining GFP+ or osterix+ cells on bone surfaces
(Figure 2D). Furthermore, no co-staining of GFP and osterix
was observed in any other region. Semiquantitative
analysis indicated the average humeral section contained
>2,800 osterix+ cells (>700 in epiphysis, >1,000 primary
spongiosa, 100 secondary spongiosa, >1,000 on endo-
cortical bone surfaces). If chimerism rates of 0.1%–1%
were achieved in the osteoblast lineage, then five to
56 GFP+ve cells would be expected within the >5,600
osterix+ osteoblasts surveyed in each mouse, rather than
the observed absence. Similarly, co-staining for GFP and
either collagen type I or the mature osteoblast marker
osteocalcin revealed complete absence of dual positive cells
(Figure S1; data not shown). This indicates that donor cells
did not contribute to osteoblast lineage cells after BM-IUT
transplantation in oim/oim mice.
In contrast to the lack of donor-derived osteoblasts, there
was a substantial contribution of donor cells to the osteo-
clast lineage. Galectin-3 staining was chosen as a surrogate
osteoclast marker for two reasons: (1) the close correlationStem Cell Rin bone-associated cells between galectin-3 expression and
activity of the classical osteoclast marker, TRAP, and (2) the
ability simultaneously to observe GFP and galectin-3 stain-
ing by epifluorescence microscopy. The proportion of
GFP+ cells on epiphyseal bone surfaces also galectin-3+
ranged from 95%–100% (Figure 2E). Furthermore, except
for instances where GFP+ cell frequency was very low
(%0.003% BM), the proportion of galectin-3+ osteoclasts
that were GFP+ ranged from 85%–95%, suggesting a prefer-
ential contribution of donor cells to the osteoclast lineage.
This pattern of GFP and galectin-3 co-localization was also
observed in primary spongiosa (Figure 2C) and on cortical
surfaces. These data indicate that the vastmajority of bone-
associated donor cells following BM-IUT in oim/oim mice
are osteoclasts.
Three of six mice had a notable fraction (1%–5%) of
bone-associated donor cells that lacked galectin-3 expres-
sion. These were most marked in mouse E426 and readily
detectable on endocortical surfaces. They lacked both
osterix and galectin-3 expression and were located in close
proximity to osterix+ osteoblasts (Figure 3). Staining for the
macrophage marker, F4/80, demonstrated these to be
osteal macrophages, (Figure 3), bone regulatory cells of
the hematopoietic lineage.Spontaneous Fractures in Chimeric oim/oimMice
Although lack of donor cell contribution to osteoblast
lineage cells largely obviates the potential for improved
bone matrix properties following BM-IUT, it does not
exclude the possibility of phenotypic benefit by alternative
mechanisms. The prevalence of spontaneous long bone
fractures in 6-week-old chimeric BM-IUT oim/oim mice
(median = 1 fracture/mouse; range = 0–4) is consistent
with observations in oim/oim mice without intervention
(Figure 4A; data not shown). Curiously, very few fractures
were observed in the four control animals that had under-
gone intrauterine injection of PBS or the four BM-IUT
animals in which no chimerism was observed (Figure 4A).
In the chimeric BM-IUT mice, no correlation was observed
between the frequency of donor chimerism and number of
spontaneous fractures (Figure 4B). Donor-derived osteo-
clasts, but not donor-derived osteoblasts, were found
within fracture sites (Figures 4C and 4D). These data
suggest no phenotypic benefit from BM-IUT in oim/oim
mice.DISCUSSION
BM-IUT in oim/oim resulted in demonstrable hemato-
poietic chimerism in 66% of mice at 6.7 weeks post-trans-
plantation, at levels of up to 1%. This is consistent with
previous reports of hematopoietic chimerism followingeports j Vol. 5 j 682–689 j November 10, 2015 j ª2015 The Authors 685
Figure 4. Donor Chimerism Did Not Pre-
vent Fractures in Osteogenesis Imper-
fecta Mice, and Donor Cells Did Not
Contribute to the Osteoblast Lineage
within Fracture Sites
(A) Occurrence of spontaneous long bone
fractures in 6-week-old mice.
(B) Fracture number plotted against
chimerism rate determined by qPCR.
(C and D) Sections of fracture callus
co-stained for donor cells (GFP), osteo-
clasts (TRAP), and either osterix (C) or
galectin-3 (D). Tb, trabecular bone.
Scale bars, 100 mm. Arrowheads indicate
the location of some GFP+ bone-associated
donor cells.BM-IUT into hematologically normal recipients (Panaroni
et al., 2009). A competitive advantage of recipient fetal
HSC over donor adult HSC in both replication rate and
early occupation of stem cell niches likely contributes to
these low levels of chimerism. Due to the hybrid strain
background of the oim/oim mice, the H-2 haplotype of
each recipient mousemay have been syngeneic (b), haploi-
dentical (b/k), or allogeneic (k) with donor cells. Had all
transplants been syngeneic, this may have increased the
frequency of chimeric mice and the levels of chimerism
observed. Hematopoietic micro-chimerism is not always
associated with donor tolerance (Kim et al., 1998), and
the frequency of chimeric recipients following allogeneic
BM-IUT declines with time post-transplant (Peranteau
et al., 2007). All chimeric mice displayed GFP+ donor cells
within the myeloid lineage (GFP+/F4/80+ macrophages),
lymphoid lineage (based on morphological identification
of GFP+ lymphocytes—being small round and primarily
consisting of nucleus), and robust numbers of bone-associ-
ated donor cells. We subsequently focused on the charac-
terization of these bone-associated donor cells.
Bone-associated donor cells were primarily located in
epiphyseal and metaphyseal regions where significant
bone turnover is occurring in maturing 6-week-old mice.
Despite the large numbers of bone-associated donor cells
following BM-IUT (up to 1,300 per longitudinal humeral
section), none expressed the osteoblast markers; osterix,
collagen type I or osteocalcin. Furthermore, endocortical686 Stem Cell Reports j Vol. 5 j 682–689 j November 10, 2015 j ª2015 Thebone surface, with which donor cells showed the least asso-
ciation, was observed to be primarily lined by osteoblasts.
Instead, bone-associated donor cells were identified as
osteoclasts (TRAP+; Galectin-3+) or osteal macrophages
(F4/80+; TRAP–) (Alexander et al., 2011). Our data docu-
ment a complete absence of donor-derived osteopoeisis
following BM-IUT in oim/oimmice and highlight the inad-
equacy of using only association with the bone-surface to
assign osteoblastic identity to donor-derived cells.
The morphology and localization of bone-associated
donor cells we describe is consistent with that seen
following BM-IUT in the BrtlIV OI model (Panaroni et al.,
2009) or bonemarrow transplantation (BMT) in adolescent
oim/oimmice (Otsuru et al., 2012). We postulate that bone-
associated donor cells observed in the BrtlIV model may
also be osteoclasts rather than osteoblasts (Panaroni et al.,
2009), as the identity of these cells was not profiled.
Colony-forming assays on recipient BM revealed donor-
derived GFP+ fibroblastic colony-forming units (CFU-F).
However, multiple cell types contribute to CFU-F including
macrophages (Xu et al., 1983), which are hematopoietic
lineage cells. The identity of bone-associated donor cells
following BMT in adolescent oim/oim is less clear (Otsuru
et al., 2012). In this very different transplant paradigm
involving recipient pre-conditioning with lethal irradia-
tion, donor cells expressed wild-type collagen type I,
but this alone is insufficient to assign osteoblastic identity.
Macrophages can express collagen type I in certainAuthors
circumstances including wound healing (Vaage and Lind-
blad, 1990; Zreiqat et al., 2003). Further in a murine BM
transplantation model, donor cells expressing GFP under
control of a 3.6-kb fragment of the COL1A1 promoter
were shown not to be functional osteoblasts (Wang et al.,
2005). Within donor animals, these reporter-expressing
cells were associated with active mineralization fronts
and early osteoblasts. Following transplantation into irra-
diated recipient mice they were frequently associated
with bone surfaces but never with active mineralization
fronts, and they failed to progress to osteocytes. Conse-
quently, we argue that there is currently no conclusive
evidence for donor osteopoeisis following BMT in models
of OI and that production of collagen by non-osteoblastic
donor cells may contribute to the transient clinical benefit
observed in patients following BM transplantation. In
our model of BM-IUT without irradiation induced injury,
we observed neither measurable phenotypic benefit
nor collagen type I expression in donor-derived osteal
macrophages.
While donor osteoblasts were absent following BM-IUT
in oim/oimmice, there was a disproportionate contribution
of donor cells to osteoclasts. Not only were 95%–100%
of bone-associated donor cells identified as TRAP+/
Galectin-3+ osteoclasts, but over 90% of osteoclasts were
GFP+. This was enumerated at the epiphyses, but was also
apparent at the primary spongiosa and fracture sites. Oste-
oclasts are multi-nucleated cells formed by cell fusion, and
a single GFP+ pre-cursor would lead to a GFP+ osteoclast.
Variation in GFP expression levels by osteoclasts is sugges-
tive of variation in the number of GFP+ precursors contrib-
uting to each osteoclast. Nonetheless, the extent of GFP+
osteoclasts (90% versus %1% assessed in qPCR of bone
marrow) represents a lineage bias, the reason for which is
unclear. While both osteoclasts and osteal macrophages,
F4/80+ which account for the galectin-3 negative bone-
associated donor cells, are derived frommyeloid precursors,
over-representation of donor cells was not observed in
osteal macrophages.
Consistent with the lack of donor osteopoeitic contribu-
tion, our data offer no support for donor chimerism
reducing spontaneous fracture rate in oim/oim mice. As at
other sites, donor cells within fractures were primarily oste-
oclasts, with an absence of donor-derived osteoblasts.
Curiously, fracture occurrence in control groups appeared
lower than expected. In our recent experience with
untreated 6-week-old oim/oim mice (n > 40), the median
number of long bone fractures is one per mouse, with
55% having at least one fracture at this age, whereas here
long bone fractures were observed in just one in four
mice for each control group; PBS injected IUT sham
and non-chimeric transplant recipients. This may reflect
selection bias toward more robust animals in the survivingStem Cell Ranalysis cohort, representing <20% of fetal PBS/BMT recip-
ients. Survival rates of 10%–60%, dependent on mouse
strain/disease model, are typical of murine IUT experi-
ments (Chan et al., 2007; Panaroni et al., 2009). Hence,
selection bias may provide an alternative explanation for
the superior bone biomechanical properties observed in
BM-IUT-treated BrtlIV mice compared with untreated
(rather than sham-operated) controls (Panaroni et al.,
2009). This emphasizes the importance of sham-operated
controls in fetal and neonatal cell therapy experiments in
OI models.
Previous evidence summarized above is insufficient to
indicate that BM cells are superior to MSC at contributing
to osteopoiesis in preclinical models of OI. We report a
lack of donor osteopoeisis following BM-IUT in oim/oim
mice, and posit that there is no adequate evidence to
date that BM-IUT yields clinical benefit in treatment of
OI. In the postnatal model of BMT following lethal irradi-
ation, a population of collagen type I-expressing donor
cells can be found on bone surfaces, with production of
normal collagen matrix by such cells potentially contrib-
uting the transient benefit observed following BM trans-
plants in OI children (Horwitz et al., 1999, 2001; Otsuru
et al., 2012). However, without demonstrating that donor
cells are true osteoblasts that contribute to mineralization,
it seems improbable that BMT alone provides sustained
clinical benefit in OI patients. Hence, we reiterate that
MSC with their demonstrable osteogenic potential remain
the obvious candidate for development of cell therapy for
OI. Systemic transplantation of murine MSC in neonatal
animals led to chimerism of up to 28% (Li et al., 2007),
but this is atypical. Fetal and neonatal transplant recipi-
ents of human fetal MSC display <5% chimerism (Guillot
et al., 2008; Li et al., 2007; Vanleene et al., 2011), with
worse results observed in older animals receiving adult
murine MSC (Otsuru et al., 2011; Pauley et al., 2014).
Several studies have shown increased bone formation
following local intra-femoral transplantation of murine
MSC in oim/oim mice (Li et al., 2010; Pauley et al.,
2014). Here, donor cells expressing a bone-specific re-
porter were localized to active mineralization fronts,
thus demonstrating donor osteopoiesis. This activity was
serially transplantable, indicating the persistence of an
osteogenic stem cell/progenitor (Pauley et al., 2014).
Such studies provide critical proof of principle of the ca-
pacity of transplanted MSC to contribute to osteopoeisis
in an OI setting. However, local transplantation is not
an ideal solution to a systemic skeletal disorder, and
the local transplantation protocols tested in preclinical
models involve onerous conditioning of recipients, such
as sublethal irradiation or concurrent whole BM trans-
plant. Successful development of cell therapy for OI re-
quires improved understanding of how to create nicheseports j Vol. 5 j 682–689 j November 10, 2015 j ª2015 The Authors 687
for MSC engraftment in order to allow sustained donor
chimerism.EXPERIMENTAL PROCEDURES
Animals and Intrauterine Transplantation
Animals were used in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes
and approved under institutional guidelines for humane use of
animals in research. Osteogenesis imperfecta (oim/oim) mice and
CAG-EGFP mice are described in the Supplemental Experimental
Procedures. Fresh bone marrow was harvested from hind-limb
long bones of 8- to 10-week-old CAG-EGFP mice, subjected to
red blood cell lysis and resuspended in PBS supplemented with
2% fetal bovine serum (FBS). Following timed matings of oim/oim
mice, pregnant dams underwent intrauterine transplantation at
embryonic day 14.5, with each fetus receiving 5 3 106 CAG-
EGFP nucleated bone marrow cells by intraperitoneal injection.
Litters of control fetuses undergoing the same surgical procedure
were injected with 10 ml PBS/2% FBS. Due to the hybrid strain
backgroundof oim/oimmice, theH-2 haplotype of recipient fetuses
may be syngeneic (b), haploidentical (b/k), or allogeneic (k) with
donor cells. Neonatal survival was assessed at P2, and mice were
monitored until tissue harvest at 6 weeks of age.
Fracture Assessment
Whole skeletal imaging was conducted on isoflorane-anesthetized
mice at 2, 4, and 6 weeks of age using the Kodak DXS 4000 Pro
System with Carestream MI 5.0.6 software (Bruker). Images were
obtained at an X-ray energy of 35 kVp, f-stop of 5.6- and 2.4-min
exposure time. Fractures were scored in humeri, femurs, and tibia
on the basis of a notable fracture callous or bone deformity.
gDNA Isolation and Assessment
Genomic DNA was isolated from bone marrow flushed from the
right femur, using QIAamp DNA mini kit (QIAGEN). TaqMan
qPCR assays determined the amount of donor specific gDNA
sequence (GFP) relative to a murine reference sequence (ApoB).
Bone marrow isolated from CAG-EGFP mice was used to generate
standard curves for quantitation.
Tissue Sectioning and Fluorescent Staining
Fluorescent staining for tartrate-resistant acid phosphatase (TRAP)
and immunofluorescent staining were conducted on longitudinal
cryosections of non-decalcified humeri supported on Kawamoto
cryofilm (Section Lab). Fluorescence images were captured by
confocal microscopy. For further details and antibodies, see
Supplemental Experimental Procedures.
Quantitative Analysis
Cryosections were visualized by epifluorescence microscopy
using an EGFP/DsRed dual band excitation filter set on an
AxioImagerM1 (Zeiss). Sectionswere scannedusing 403 objective,
and the number of positive staining cells were enumerated at
morphologically distinct regions of interest: epiphyses (bone
marrow and bone surface), growth plate, trabecular bone (primary688 Stem Cell Reports j Vol. 5 j 682–689 j November 10, 2015 j ª2015 Theand secondary spongiosa), cortical bone, and bone marrow. For
further details, see Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and one figure and can be foundwith this article online
at http://dx.doi.org/10.1016/j.stemcr.2015.09.017.
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